A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs

References

• Pharmaceuticals: A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100(Pt A):1–401 (2012).
   Google Scholar
• Sorsa, M., and D. Anderson: Monitoring of occupational exposure to cytostatic anticancer agents. Mutat. Res. 355(1–2):253–261 (1996).
   PubMed Web of Science ®Google Scholar
• NIOSH: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health DHHS (NIOSH) Publication No 2004 (165) (2004).
   Google Scholar
• Suspiro, A., and J. Prista: Biomarkers of occupational exposure do anticancer agents: a minireview. Toxicol. Lett. 207(1):42–52 (2011).
   PubMed Web of Science ®Google Scholar
• Baker, E.S., and T.H. Connor: Monitoring occupational exposure to cancer chemotherapy drugs. Am. J. Health Syst. Pharm. 53(22):2713–2723 (1996).
   PubMed Web of Science ®Google Scholar
• Sessink, P.J., and R.P. Bos: Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 20(4):347–359 (1999).
   PubMed Web of Science ®Google Scholar
• Turci, R., C. Sottani, G. Spagnoli, and C. Minoia: Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 789(2):169–209 (2003).
   PubMed Web of Science ®Google Scholar
• Hedmer, M., P. Hoglund, E. Cavallin-Stahl, M. Albin, and B.A. Jonsson: Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients. Int. Arch. Occup. Environ. Health 81(3):285–293 (2008).
   PubMed Web of Science ®Google Scholar
• Easty, A.C., N. Coakle, R. Cheng, et al.: Safe handling of cytotoxics: guideline recommendations. Curr. Oncol. 22(1):E27–E37 (2015).
   Google Scholar
• Sessink, P.J., B.C. Wittenhorst, R.B. Anzion, and R.P. Bos: Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch. Environ. Health 52(3):240–244 (1997).
   PubMed Web of Science ®Google Scholar
• Kromhout, H., F. Hoek, R. Uitterhoeve, et al.: Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann. Occup. Hyg. 44(7):551–560 (2000).
   PubMed Web of Science ®Google Scholar
• Hon, C.Y., C. Barzan, and G. Astrakianakis: Identification of knowledge gaps regarding healthcare workers' exposure to antineoplastic drugs: review of literature, North America versus Europe. Saf. Health Work 5(4):169–174 (2014).
   PubMedGoogle Scholar
• Schierl, R., A. Bohlandt, and D. Nowak: Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann. Occup. Hyg. 53(7):703–711 (2009).
   PubMed Web of Science ®Google Scholar
• Hedmer, M., and G. Wohlfart: Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. J. Environ. Monit. 14(7):1968–1975 (2012).
   PubMedGoogle Scholar
• Kiffmeyer, T.K., J. Tuerk, M. Hahn, et al.: Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies - the MEWIP project. Ann. Occup. Hyg. 57(4):444–455 (2013).
   PubMed Web of Science ®Google Scholar
• Gabay, M.: USP <800>: Handling hazardous drugs. Hosp. Pharm. 49(9):811–812 (2014).
   PubMedGoogle Scholar
• Sessink, P.J.: Environmental contamination with cytostatic drugs: past, pesent and future. Saf. Consid. Oncol. Pharm. 1–3 (2011).
   Google Scholar
• Ziegler, E., H.J. Mason, and P.J. Baxter: Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup. Environ. Med. 59(9):608–612 (2002).
   PubMed Web of Science ®Google Scholar
• Sessink, P.J., J.L. Timmersmans, R.B. Anzion, and R.P. Bos: Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of alpha-fluoro-beta-alanine in urine. J. Occup. Med. 36(1):79–83 (1994).
   PubMedGoogle Scholar
• Sessink, P.J., R.B. Anzion, P.H. Van den Broek, and R.P. Bos: Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm. Weekbl. Sci. 14(1):16–22 (1992).
   PubMedGoogle Scholar
• Sessink, P.J., J.H. de Roos, F.H. Pierik, R.B. Anzion, and R.P. Bos: Occupational exposure of animal caretakers to cyclophosphamide. J. Occup. Med. 35(1):47–52 (1993).
   PubMedGoogle Scholar
• Wick, C., M.H. Slawson, J.A. Jorgenson, and L.S. Tyler: Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am. J. Health Syst. Pharm. 60(22):2314–2320 (2003).
   PubMed Web of Science ®Google Scholar
• Hedmer, M., H. Tinnerberg, A. Axmon, and B.A. Jonsson: Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int. Arch. Occup. Environ. Health 81(7):899–911 (2008).
   PubMed Web of Science ®Google Scholar
• Maeda, S., K. Miyawaki, S. Matsumoto, M. Oishi, Y. Miwa, and N. Kurokawa: Evaluation of environmental contaminations and occupational exposures involved in preparation of chemotherapeutic drugs. Yakugaku Zasshi 130(6):903–910 (2010).
   PubMed Web of Science ®Google Scholar
• Sottani, C., B. Porro, M. Comelli, M. Imbriani, and C. Minoia: An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(27):2593–2605 (2010).
   PubMed Web of Science ®Google Scholar
• Yoshida, J., S. Koda, S. Nishida, T. Yoshida, K. Miyajima, and S. Kumagai: Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. J. Oncol. Pharm. Pract. 17(1):29–38 (2011).
   PubMedGoogle Scholar
• Sugiura, S., M. Asano, K. Kinoshita, M. Tanimura, and T. Nabeshima: Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J. Oncol. Pharm. Pract. 17(1):14–19 (2011).
   PubMedGoogle Scholar
• Sugiura, S., H. Nakanishi, M. Asano, et al.: Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan. J. Oncol. Pharm. Pract. 17(1):20–28 (2011).
   PubMedGoogle Scholar
• Turci, R., C. Minoia, C. Sottani, et al.: Occupational exposure to antineoplastic drugs in seven Italian hospitals: the effect of quality assurance and adherence to guidelines. J. Oncol. Pharm. Pract. 17(4):320–332 (2011).
   PubMedGoogle Scholar
• Sottani, C., B. Porro, M. Imbriani, and C. Minoia: Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicol. Lett. 213(1):107–115 (2012).
   PubMed Web of Science ®Google Scholar
• Kopp, B., S. Crauste-Manciet, A. Guibert, et al.: Environmental and biological monitoring of platinum-containing drugs in two hospital pharmacies using positive air pressure isolators. Ann. Occup. Hyg. 57(3):374–383 (2013).
   PubMed Web of Science ®Google Scholar
• Sessink, P.J., G.M. Leclercq, D.M. Wouters, L. Halbardier, C. Hammad, and N. Kassoul: Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. J. Oncol. Pharm. Pract. 21(2):118–127 (2014).
   Google Scholar
• Mason, H.J., S. Blair, C. Sams, et al.: Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann. Occup. Hyg. 49(7):603–610 (2005).
   PubMed Web of Science ®Google Scholar
• Fransman, W., S. Peelen, S. Hilhorst, N. Roeleveld, D. Heederik, and H. Kromhout: A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann. Occup. Hyg. 51(3):231–239 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshida, J., G. Tei, C. Mochizuki, Y. Masu, S. Koda, and S. Kumagai: Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann. Occup. Hyg. 53(2):153–160 (2009).
   PubMed Web of Science ®Google Scholar
• Tanimura, M., K. Yamada, S. Sugiura, et al.: An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese Community Hospital designated for the treatment of cancer. J. Health Sci. 55(5):750–756 (2009).
   Google Scholar
• Connor, T.H., D.G. DeBord, J.R. Pretty, et al.: Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J. Occup. Environ. Med. 52(10):1019–1027 (2010).
   PubMed Web of Science ®Google Scholar
• Sabatini, L., A. Barbieri, V. Lodi, and F.S. Violante: Biological monitoring of occupational exposure to antineoplastic drugs in hospital settings. Med. Lav. 103(5):394–401 (2012).
   PubMed Web of Science ®Google Scholar
• Yoshida, J., S. Koda, S. Nishida, H. Nakano, G. Tei, and S. Kumagai: Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Ann. Occup. Hyg. 57(2):251–260 (2013).
   PubMed Web of Science ®Google Scholar
• Ramphal, R., T. Bains, R. Vaillancourt, M.H. Osmond, and N. Barrowman: Occupational Exposure to Cyclophosphamide in Nurses at a Single Center. J. Occup. Environ. Med. 56(3):304–312 (2014).
   PubMed Web of Science ®Google Scholar
• Sessink, P.J., K.A. Boer, A.P. Scheefhals, R.B. Anzion, and R.P. Bos: Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int. Arch. Occup. Environ. Health 64(2):105–112 (1992).
   PubMed Web of Science ®Google Scholar
• Ursini, C.L., D. Cavallo, A. Colombi, M. Giglio, A. Marinaccio, and S. Iavicoli: Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs. Int. Arch. Occup. Environ. Health 80(2):134–140 (2006).
   PubMed Web of Science ®Google Scholar
• Villarini, M., L. Dominici, R. Piccinini, et al.: Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs. Mutagenesis 26(3):359–369 (2011).
   PubMed Web of Science ®Google Scholar
• Ramphal, R., T. Bains, G. Goulet, and R. Vaillancourt: Occupational exposure to chemotherapy of pharmacy personnel at a single centre. Can. J. Hosp. Pharm. 68(2):104–112 (2015).
   PubMedGoogle Scholar
• Cavallo, D., C.L. Ursini, B. Perniconi, et al.: Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat. Res. 587(1–2):45–51 (2005).
   PubMed Web of Science ®Google Scholar
• Konate, A., J. Poupon, A. Villa, et al.: Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J. Surg. Oncol. 103(1):6–9 (2011).
   PubMed Web of Science ®Google Scholar
• Sessink, P.J., M. Cerna, P. Rossner, et al.: Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat. Res. 309(2):193–199 (1994).
   PubMed Web of Science ®Google Scholar
• Manno, M., C. Viau, J. Cocker, et al.: Biomonitoring for occupational health risk assessment (BOHRA). Toxicol. Lett. 192(1):3–16 (2010).
   PubMed Web of Science ®Google Scholar
• Jeronimo, M., M. Colombo, G. Astrakianakis, and C.Y. Hon: A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal. Bioanal. Chem. 407(23):7083–7092 (2015).
   PubMed Web of Science ®Google Scholar